Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 2/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 3/20 | 0.36 |
| ▸ | DRD4 | P21917 | 3/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7005994 | 0.85 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4DESR2 | |
| SCHEMBL13454021 | 0.81 | MAPT (0.52) | PDE4APDE4BPDE4CPDE4DHTR2A | |
| SCHEMBL29496819 | 0.81 | MAPT (0.52) | PDE4APDE4BPDE4CPDE4DHTR2A | |
| SCHEMBL7004062 | 0.79 | ESR2 (0.50) | PDE4APDE4BPDE4CPDE4DESR2 | |
| SCHEMBL735604 | 0.79 | ESR2 (0.50) | PDE4APDE4BPDE4CPDE4DESR2 | |
| SCHEMBL7004274 | 0.79 | ESR2 (0.50) | PDE4APDE4BPDE4CPDE4DESR2 | |
| SCHEMBL7005918 | 0.77 | HTR2C (0.53) | PDE4APDE4BPDE4CPDE4DHTR2A | |
| SCHEMBL2884802 | 0.76 | HTR2C (0.46) | ESR2HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL7005602 | 0.76 | PDE4A (0.48) | PDE4APDE4BPDE4CPDE4DMAPT | |
| SCHEMBL3703094 | 0.76 | ESR2 (0.50) | PDE4APDE4BPDE4CPDE4DESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133140-B2 | Cycloalkylamne derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-09-15 | — | — | US | disclosed |
| US-20120295943-A9 | CYCLOALKYLAMINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-11-22 | — | — | US | disclosed |
| US-20120122941-A1 | CYCLOALKYLAMINE DERIVATIVES | MARUMOTO SHINJI (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295943-A9 | CYCLOALKYLAMINE DERIVATIVES | CASR, CALCR, CALCRL | PDE4A 1818/4885PDE4B 1913/4885PDE4C 3068/4885 |
| US-20120122941-A1 | CYCLOALKYLAMINE DERIVATIVES | CASR, CALCR, CALCRL | PDE4A 1818/4885PDE4B 1913/4885PDE4C 3068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.